Paxlovid is (1) authorized for > the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients with positive results of dir

Paxlovid is (1) authorized for > the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death It's not that everyone with a Covid infection will get the drug. That number should be far lower than 3.7% of the population, most of which will either be asymptomatic or likely won't require hospitalization due to low risk. I wonder what that means for your calculation. (1) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/coronavi...